Skip to content

Study · Animal study (in vivo) · 2024

2 results

The Role of Macrophage Efferocytosis in the Pathogenesis of Apical Periodontitis.

Guan X, Wang Y, Li W, Mu W, Tang Y, Wang M, Seyam A, Yang Y, Pan L, Hou T

International journal of molecular sciences29 Mar 2024Cited by 17 (Europe PMC)

PMID38612664 (opens in a new tab)PMCIDPMC11011522 (opens in a new tab)DOI10.3390/ijms25073854 (opens in a new tab)PepBankPUB-38612664
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Macrophages (Mφs) play a crucial role in the homeostasis of the periapical immune micro-environment caused by bacterial infection. Mφ efferocytosis has been demonstrated to promote the resolution of multiple infected diseases via accelerating Mφ polarization into M2 type. However, the Mφ efferocytosis-apical periodontitis (AP) relationship has not been elucidated yet. This study aimed to explore the role of Mφ efferocytosis in the pathogenesis of AP. Clinical specimens were collected to determine the involvement of Mφ efferocytosis in the periapical region via immunohistochemical and immunofluorescence staining. For a further understanding of the moderator effect of Mφ efferocytosis in the pathogenesis of AP, both an in vitro AP model and in vivo AP model were treated with ARA290, a Mφ efferocytosis agonist. Histological staining, micro-ct, flow cytometry, RT-PCR and Western blot analysis were performed to detect the inflammatory status, alveolar bone loss and related markers in AP models. The data showed that Mφ efferocytosis is observed in the periapical tissues and enhancing the Mφ efferocytosis ability could effectively promote AP resolution via facilitating M2 Mφ polarization. Collectively, our study demonstrates the functional importance of Mφ efferocytosis in AP pathology and highlights that accelerating Mφ efferocytosis via ARA290 could serve as an adjuvant therapeutic strategy for AP.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In apical periodontitis models, enhancing macrophage efferocytosis with ARA290 promoted M2 macrophage polarization.

    In plain wordsIn disease models of tooth-root inflammation, ARA290 helped macrophages shift to the M2 type.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    IncreaseM2 macrophage polarization
    Study

    n: not reported in source

    In vitro and in vivo apical periodontitis (AP) models
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data showed that Mφ efferocytosis is observed in the periapical tissues and enhancing the Mφ efferocytosis ability could effectively promote AP resolution via facilitating M2 Mφ polarization.
    1 context sentence
    Summary · context
    For a further understanding of the moderator effect of Mφ efferocytosis in the pathogenesis of AP, both an in vitro AP model and in vivo AP model were treated with ARA290, a Mφ efferocytosis agonist.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In apical periodontitis models, enhancing macrophage efferocytosis with ARA290 promoted resolution of apical periodontitis.

    In plain wordsIn disease models of tooth-root inflammation, ARA290 helped the inflammation to resolve.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    Not applicableResolution of apical periodontitis
    Study

    n: not reported in source

    In vitro and in vivo apical periodontitis (AP) models
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data showed that Mφ efferocytosis is observed in the periapical tissues and enhancing the Mφ efferocytosis ability could effectively promote AP resolution via facilitating M2 Mφ polarization.
    1 context sentence
    Summary · context
    For a further understanding of the moderator effect of Mφ efferocytosis in the pathogenesis of AP, both an in vitro AP model and in vivo AP model were treated with ARA290, a Mφ efferocytosis agonist.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.